文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

加拿大 20 多年来癌症网络生存率的进展。

Progress in net cancer survival in Canada over 20 years.

机构信息

Health Statistics Division, Statistics Canada, Ottawa, Ontario.

出版信息

Health Rep. 2018 Sep 19;29(9):10-18.


DOI:
PMID:30230521
Abstract

BACKGROUND: Monitoring the progress of cancer survival in a population over time is an important part of cancer surveillance. DATA AND METHODS: Data are from the Canadian Cancer Registry with mortality follow-up through record linkage to the Canadian Vital Statistics Death Database and tax files. Net survival (NS) was derived using the Pohar Perme method. Predicted estimates of NS for the period from 2012 to 2014 were calculated using the period method. Age-standardized and age-specific changes in five-year NS between the periods from 1992 to 1994 and 2012 to 2014 were determined for 30 individual cancers. RESULTS: Predicted five-year NS for 2012 to 2014 ranged from 98% for thyroid cancer to 7% for mesothelioma. Between 1992 to 1994 and 2012 to 2014, improvements in five-year age standardized NS were greatest for chronic myeloid leukemia (23.9 percentage points), though a large majority of the increase occurred in the first decade. Increases exceeding 15.0 percentage points were also observed for non-Hodgkin lymphoma (19.5), cancer of the small intestine (17.4) and multiple myeloma (16.9). In contrast, little to no improvement was observed for cancers of the anus, larynx, soft tissue or uterus, or for mesothelioma. Increases in five-year NS were greatest for chronic myeloid leukemia in each age group with the exception of those aged 75 to 84 years (thyroid). DISCUSSION: This study reveals important areas of progress in cancer outcomes in Canada since the early 1990s. It also sheds light on cancers for which there has seemingly been no improvement in five-year net survival over a 20-year period.

摘要

背景:监测人群中癌症生存状况的进展是癌症监测的重要组成部分。

数据和方法:数据来自加拿大癌症登记处,通过与加拿大生命统计死亡数据库和税务档案的记录链接进行死亡率随访。使用 Pohar Perme 方法得出净生存率 (NS)。使用期间法计算 2012 年至 2014 年期间 NS 的预测估计值。确定了 30 种个别癌症在 1992 年至 1994 年和 2012 年至 2014 年期间,五年 NS 的年龄标准化和年龄特异性变化。

结果:预测 2012 年至 2014 年的五年 NS 范围从甲状腺癌的 98%到间皮瘤的 7%。在 1992 年至 1994 年和 2012 年至 2014 年之间,慢性髓性白血病的五年年龄标准化 NS 改善最大(23.9 个百分点),尽管大部分改善发生在第一个十年。非霍奇金淋巴瘤(19.5)、小肠癌(17.4)和多发性骨髓瘤(16.9)的增加也超过了 15.0 个百分点。相比之下,肛门癌、喉癌、软组织癌或子宫癌以及间皮瘤的改善微乎其微。除了 75 至 84 岁年龄组(甲状腺)外,慢性髓性白血病的五年 NS 增加在每个年龄组都最大。

讨论:本研究揭示了自 20 世纪 90 年代初以来加拿大癌症结局的重要进展领域。它还揭示了在 20 年期间,五年净生存率似乎没有改善的癌症。

相似文献

[1]
Progress in net cancer survival in Canada over 20 years.

Health Rep. 2018-9-19

[2]
Trends in paediatric cancer survival in Canada, 1992 to 2017.

Health Rep. 2021-2-17

[3]
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.

Epidemiol Prev. 2016

[4]
Changing trends in thyroid cancer incidence in Canada: A histologic examination, 1992 to 2016.

Health Rep. 2020-1-15

[5]
Italian cancer figures, report 2012: Cancer in children and adolescents.

Epidemiol Prev. 2013

[6]
Differences in cancer survival in Canada by sex.

Health Rep. 2016-4

[7]
Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods.

Int J Cancer. 2012-10-3

[8]
Survival of solid cancer patients in France, 1989-2013: a population-based study.

Eur J Cancer Prev. 2017-11

[9]
Increasing survival from leukemia among adolescents and adults in Canada: A closer look.

Health Rep. 2016-7-20

[10]
Five-year cancer survival by stage at diagnosis in Canada.

Health Rep. 2023-1-18

引用本文的文献

[1]
Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study.

Int J Cancer. 2025-7-1

[2]
Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer.

Clin Transl Gastroenterol. 2025-1-1

[3]
Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care.

Syst Rev. 2024-3-16

[4]
Exploring the Future of Cancer Impact in Alberta: Projections and Trends 2020-2040.

Curr Oncol. 2023-11-18

[5]
Assessing the Efficacy of a 28-Day Comprehensive Online Prostate Cancer Patient Empowerment Program (PC-PEP) in Facilitating Engagement of Prostate Cancer Patients in Their Survivorship Care: A Qualitative Study.

Curr Oncol. 2023-9-21

[6]
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.

Curr Oncol. 2023-8-8

[7]
The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010-2017), and the Survival of Patients Diagnosed with CNS Tumours (2008-2017).

Curr Oncol. 2023-4-20

[8]
Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study.

BMC Cancer. 2022-12-14

[9]
Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec.

Curr Oncol. 2022-11-12

[10]
Predicting recurrence risks in lung cancer patients using multimodal radiomics and random survival forests.

J Med Imaging (Bellingham). 2022-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索